| |
|
|
|
|
|
 |
| |
|
´ëÇÑÇÁ·ÎÄ«ÀÎ2%ÁÖ(ÇÁ·ÎÄ«Àο°»ê¿°) 20mL Procaine inj. 2% Daihan
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645101031
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/20mL/º´(2024.11.01)(ÇöÀç¾à°¡)
\300 ¿ø/20mL/º´(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾×ÀÌ µé¾î ÀÖ´Â ¹«»öÅõ¸íÇÑ ¹ÙÀ̾ËÀÌ´Ù. [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10¹ÙÀ̾Ë/»óÀÚ(20mL/¹ÙÀ̾Ë) |
| ÁÖ¼ººÐÄÚµå |
218230BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
°æ¸·¿Ü¸¶Ãë, Àü´Þ¸¶Ãë
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û ¼ºÀÎ
1. °æ¸·¿Ü¸¶Ãë(±âÁØ ÃÖ°í¿ë·® 1ȸ 600§·) : ÇÁ·ÎÄ«Àο°»ê¿°À¸·Î¼ º¸Åë ¼ºÀÎ 300-400§·À» Åõ¿©ÇÑ´Ù.
2. Àü´Þ¸¶Ãë : ÇÁ·ÎÄ«Àο°»ê¿°À¸·Î¼ º¸Åë ¼ºÀÎ 10-400§·À» Åõ¿©ÇÑ´Ù.
Çʿ信 µû¶ó ¿¡Çdz×ÇÁ¸°(º¸Åë ³óµµ 1 : 10-20¸¸)À» ÷°¡ÇÏ¿© »ç¿ëÇÑ´Ù.
¿¬·É, ¸¶Ã뿵¿ª, ºÎÀ§, Á¶Á÷, Áõ»ó, üÁú, Àü½Å»óÅ¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) (°æ¸·¿Ü¸¶Ãë) ÁßÁõÀÇ ÃâÇ÷ ¶Ç´Â ¼ï »óÅÂÀÇ È¯ÀÚ
2) (°æ¸·¿Ü¸¶Ãë) ÁÖ»çºÎÀ§ ¶Ç´Â ±× ÁÖÀ§¿¡ ¿°Áõ ȯÀÚ
3) (°æ¸·¿Ü¸¶Ãë) ÆÐÇ÷Áõ ȯÀÚ
4) ¸ÞÆ®Çì¸ð±Û·ÎºóÇ÷Áõ ȯÀÚ
5) ÀÌ ¾à ¶Ç´Â ±âŸÀÇ ¾È½ÄÇâ»ê¿¡½ºÅ׸£(ÄÚÄ«ÀÎ Á¦¿Ü)°è ±¹¼Ò¸¶ÃëÁ¦¿¡ °ú¹ÎÁõ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
(°æ¸·¿Ü¸¶Ãë) ´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.
1) ÁßÃ߽Űæ°è Áúȯ(¼ö¸·¿°, ȸ¹éô¼ö¿° µî) ȯÀÚ
2) ÀÓ»êºÎ
3) °í·ÉÀÚ
4) Ç÷¾× Áúȯ ¶Ç´Â Ç×ÀÀ°íÁ¦ Åõ¿© ȯÀÚ
5) ÁßÁõÀÇ °íÇ÷¾Ð ȯÀÚ
6) ôÁÖ¿¡ ÇöÀúÇÑ º¯Çü ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï : ¼ïÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí Ç÷¾ÐÀúÇÏ, ¾È¸éâ¹é, ¸Æ¹Ú ÀÌ»ó, È£Èí¾ïÁ¦ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©ÁßÁöÇϰí ÀΰøÈ£Èí, »ê¼ÒÈíÀÔ, ¼ö¾×, ź»ê³ªÆ®·ý, Ç÷¾Ð»ó½ÂÁ¦ Åõ¿©, ÀûÀýÇÑ Ã¼À§ À¯Áö µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) ÁßÃ߽Űæ°è
¨ç ÁøÀü, °æ·Ã µîÀÇ Áßµ¶ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©ÁßÁöÇÏ°í µð¾ÆÁ¦ÆÊ ¶Ç´Â Ãʴܽð£Çü ¹Ù¸£ºñÅ»»ê Á¦Á¦(Ä¡¿ÀÆæÅ»³ªÆ®·ý) Åõ¿© µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
¨è Á¹À½, ºÒ¾È, ÈïºÐ, ¹«½Ã, ¾îÁö·¯¿ò, ±¸¿ª․±¸Åä, µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ¿© ¼ï ¶Ç´Â Áßµ¶ÇÑ Áõ»óÀ¸·Î ÀÌÇàÇÏ´Â °Í¿¡ ÁÖÀÇÇϰí Çʿ信 µû¶ó ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) Ç÷¾× : µå¹°°Ô ¸ÞÆ®Çì¸ð±Û·ÎºóÇ÷ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) °ú¹ÎÁõ : µÎµå·¯±â µîÀÇ ÇǺÎÁõ»ó, ºÎÁ¾ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©ÁßÁöÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ´ÙÀ½ ȯÀÚ¿¡ Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â Ç÷°ü¼öÃàÁ¦(¿¡Çdz×ÇÁ¸°, ³ë¸£¿¡Çdz×ÇÁ¸°)À» ÷°¡ÇÏÁö ¾Ê´Â´Ù.
¨ç Ç÷°ü¼öÃàÁ¦¿¡ °ú¹ÎÁõ ȯÀÚ
¨è °íÇ÷¾Ð, µ¿¸Æ°æÈ, ½ÉºÎÀü, °©»ó¼±±â´ÉÇ×Áø, ´ç´¢º´, Ç÷°ü°æ·Ã µîÀÌ Àִ ȯÀÚ
¨é (ħÀ±․Àü´Þ¸¶Ãë) ±Í, ¼Õ°¡¶ô․¹ß°¡¶ô ¶Ç´Â À½°æÀÇ ¸¶Ãë
2) ´ÙÀ½ ȯÀÚ¿¡ Ç÷°ü¼öÃàÁ¦(¿¡Çdz×ÇÁ¸°, ³ë¸£¿¡Çdz×ÇÁ¸°)¸¦ ÷°¡ÇÏ¿© Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
¨ç ÇÒ·Îź µîÀÇ ÇÒ·Î°Õ ÇÔÀ¯ ÈíÀÔ¸¶ÃëÁ¦ Åõ¿© ȯÀÚ
¨è »ïȯ°è Ç׿ì¿ï¾à ¶Ç´Â MAOÀúÇØÁ¦ Åõ¿©ÁßÀΠȯÀÚ |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Procaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
|
| Pharmacology |
Procaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine.
|
| Protein Binding |
Procaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Procaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 7.7 minutes
|
| Absorption |
Procaine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Procaine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : ÁÖ»çÁ¦ : 2-5ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 0.5-1.5 ½Ã°£ (ȯÀÚ, Â÷´Ü¹æ¹ý, ³óµµ, ¸¶Ãë¹æ¹ý¿¡ ÀÇÁ¸Àû)
- ´ë»ç : Ç÷Àå È¿¼Ò¿¡ ÀÇÇØ p-aminobenzoic acid, diethylaminoethanol·Î ºü¸£°Ô °¡¼öºÐÇØµÊ. ¹è¼³µÇ±â Àü¿¡ 80%´Â Æ÷ÇÕµÊ
- ¹Ý°¨±â : 7.7ºÐ
- ¼Ò½Ç : ´ë»çü ¹× ÀϺΠ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Biotransformation |
Procaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hydrolysis by plasma esterases to PABA
|
| Toxicity |
Procaine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Procaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aluminium Formation of non-absorbable complexesBismuth Formation of non-absorbable complexesCalcium Formation of non-absorbable complexesDihydroxyaluminium Formation of non-absorbable complexesEstramustine Increases the levels of estramustineMagnesium oxide Formation of non-absorbable complexesMagnesium Formation of non-absorbable complexesSucralfate Formation of non-absorbable complexesIron Formation of non-absorbable complexes
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Procaine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Procaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). [PubChem]
|
| Drug Category |
Procaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalLocal Anesthetics
|
| Smiles String Canonical |
Procaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
|
| Smiles String Isomeric |
Procaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
|
| InChI Identifier |
Procaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3
|
| Chemical IUPAC Name |
Procaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylaminoethyl 4-aminobenzoate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|